PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

Beyhan Ataseven,1,2 Angela Gunesch,2 Wolfgang Eiermann,3 Ronald E Kates,4 Bernhard Högel,5 Pjotr Knyazev,6 Axel Ullrich,6 Nadia Harbeck4 1Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany;...

Full description

Bibliographic Details
Main Authors:	Ataseven B, Gunesch A, Eiermann W, Kates RE, Högel B, Knyazev P, Ullrich A, Harbeck N
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-10-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/ptk7-as-a-potential-prognostic-and-predictive-marker-of-response-to-ad-peer-reviewed-article-OTT

Similar Items

PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.
by: Silvia Gärtner, et al.
Published: (2014-01-01)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
by: Wanjing Chen, et al.
Published: (2021-02-01)

PTK-7 Expression in Gastric Cancer: A Prognostic Determinant
by: Melike Özçelik, et al.
Published: (2020-03-01)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
by: Eleni Timotheadou, et al.
Published: (2017-08-01)

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
by: George Fountzilas, et al.
Published: (2012-01-01)

PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer
by: Bo Chen, et al.
Published: (2020-11-01)

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
by: Donnez Jacques, et al.
Published: (2008-02-01)

MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
by: P. V. Kazantseva, et al.
Published: (2016-07-01)

Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
by: Treya M. Long, et al.
Published: (2019-08-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
by: Jeong Seong Hyun, et al.
Published: (2011-08-01)

First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
by: S. G. Kanorskiy, et al.
Published: (2019-10-01)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
by: Hitomi Mori, et al.
Published: (2016-01-01)

Response and Long-Term Effect of Patients with Triple-Negative Breast Cancer Receiving Neo-Adjuvant Anthracycline-Based Chemotherapy
by: Zhengkui SUN, Xingtian MA, Yudong WU
Published: (2009-06-01)

STRATEGY FOR THE USE OF ERYTHROPOETIN ALPHA TO MAINTAIN HEMOGLOBIN LEVEL IN BREAST CANCER PATIENT TREATED WITH ANTHRACYCLINE-BASE OF ADJUVANT CHEMOTHERAPY
by: Dimyati Achmad, et al.
Published: (2015-07-01)

BRCA2 mutations and triple-negative breast cancer.
by: Peter Meyer, et al.
Published: (2012-01-01)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
by: Francesca Castoldi, et al.
Published: (2019-01-01)

Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial
by: Ke-Da Yu, et al.
Published: (2021-06-01)

Adjuvant Chemotherapy of Early Stage Breast Cancer in Community-based Cancer Treatment Fields: CMF Compared with Anthracycline/Taxane-based Regimens
by: Narges Bayat Mokhtari, et al.
Published: (2017-04-01)

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
by: Kristen D Starbuck, et al.
Published: (2018-01-01)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
by: Susini T, et al.
Published: (2014-11-01)

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
by: Blaes AH, et al.
Published: (2015-11-01)

The function of PTK7 during Xenopus neural crest migration
by: Shnitsar, Iryna
Published: (2009)

Identification and functional characterization of PTK7 ligands in Xenopus laevis
by: Peradziryi, Hanna
Published: (2011)

PTK7 marks the first human developmental EMT in vitro.
by: David N Chan, et al.
Published: (2012-01-01)

Electrocardiographic characteristics of Nigerian children on anthracycline-based chemotherapy: A preliminary report
by: I D Peter, et al.
Published: (2017-01-01)

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
by: Clausen MR, et al.
Published: (2019-11-01)

Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain
by: Benedict T. Costello, MBBS, PhD, et al.
Published: (2019-12-01)

The effect of anthracyclines in minimal doses on cardiac function of children under chemotherapy
by: Shiva Rahimi Dehgolan, et al.
Published: (2014-07-01)

Expression levels of PTK7, HER-2 and Mcm5 proteins in esophageal squamous cell carcinoma and their clinical prognostic value
by: Shi-Qiong Yi, et al.
Published: (2019-08-01)

Uncontrolled arterial hypertension in patients with breast cancer and the risk of developing cardiotoxicity with anthracycline-containing chemotherapy
by: Elena V Oshchepkova, et al.
Published: (2019-12-01)

Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer
by: Bacinschi XE, et al.
Published: (2020-11-01)

S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma
by: Katono K, et al.
Published: (2017-11-01)

Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance
by: Zhao C, et al.
Published: (2013-03-01)

PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer
by: Darren J. Wozniak, et al.
Published: (2017-11-01)

Protein Tyrosine Kinase 7 (PTK7) as a Predictor of Lymph Node Metastases and a Novel Prognostic Biomarker in Patients with Prostate Cancer
by: Hongtuan Zhang, et al.
Published: (2014-07-01)

The Increased PTK7 Expression Is a Malignant Factor in Cervical Cancer
by: Jun-Jie Sun, et al.
Published: (2019-01-01)

PTK7 protein localization and stability is affected by canonical Wnt ligands
by: Berger, Hanna Irena
Published: (2016)

Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer
by: Onur Esbah, et al.
Published: (2017-01-01)

Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC.
by: Hongliang Yu, et al.
Published: (2020-01-01)